Crinetics Pharmaceuticals (CRNX) has provided an update.
Crinetics Pharmaceuticals, Inc. has introduced a new Excess Deferral Plan for a select group of its top management and highly compensated employees, including executive officers and non-employee directors. This non-qualified deferred compensation plan allows participants to defer portions of their salary, bonuses, and stock awards, with the company potentially making matching or discretionary contributions. Funds in the plan are treated as investments, with earnings or losses reflecting the performance of the selected options. Participants have immediate vesting rights for their contributions and the company’s matching funds, while discretionary contributions vest according to a set schedule, with non-vested funds forfeited upon leaving the company.
Learn more about CRNX stock on TipRanks’ Stock Analysis page.
